Long-term safety and cholesterol lowering in children with familial hypercholesterolemia
Treatments studied
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study is checking the long-term safety and how well a new injectable medicine (lerodalcibep) works to lower cholesterol in children and teens with familial hypercholesterolemia (an inherited condition causing very high cholesterol). It's for those who already finished an earlier study of this same medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have taken part in and completed the earlier study (LIB003-008) of this same medicine.
- Age: 6 to 17 years old (they were 6–17 when starting the earlier study).
- Weight: more than 40 pounds (18 kg), and body mass index (BMI) between 17 and 42.
- On a stable diet and cholesterol-lowering medication (like statins or ezetimibe) for at least 4 weeks.
- Not using certain other cholesterol drugs (e.g., mipomersen, lomitapide, gemfibrozil).
- Must be able to attend scheduled study visits and, if sexually active and able to become pregnant, agree to use highly effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called QLC7401 for people with a genetic condition called heterozygous familial hypercholesterolemia, which causes very high cholesterol. It aims to see if the new medicine can further lower bad cholesterol when added to your usual cholesterol treatments.
This study tests an experimental daily pill (enlicitide decanoate) that lowers LDL ('bad') cholesterol in children and teens with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to see if this medicine can safely help reduce their high cholesterol levels.
This study tests a new injection called SYH2053 for people with HeFH, a genetic condition that causes very high cholesterol. It looks at whether the injection can safely lower LDL cholesterol when added to standard statin therapy.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This Phase 3 study looks at the long-term safety and benefit of OLE LIB003 for people with very high cholesterol or heart disease risk who still need lower LDL (“bad cholesterol”). It’s likely a continuation study for participants who already did earlier LIB003 Phase 3 trials.
This study tests a new injection called ART002g1 for people with an inherited form of high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if it is safe and can help lower cholesterol levels.
Hear when a new Heterozygous Familial Hypercholesterolemia (HeFH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.